The Roche GENERATION-HD1 global phase 3 trial of tominersen (RG6042), an antisense oligonucleotide, completed enrollment in 2020, with 791 participants enrolled across approximately 100 sites in 18 countries.
Study treatment and follow-up assessments are ongoing, and on completion, participants are offered the opportunity to enroll in the open-label extension (OLE) study, GEN-EXTEND.
More info here